Literature DB >> 18632517

Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash.

Aminah Jatoi1.   

Abstract

Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

Entities:  

Year:  2007        PMID： 18632517     DOI： 10.3816/SCT.2007.n.015

Source DB:  PubMed          Journal:  Support Cancer Ther        ISSN： 1543-2912


  4 in total

Review 1.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

2.  Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).

Authors:  Pamela J Atherton; Kelli N Burger; Charles L Loprinzi; Michelle A Neben Wittich; Robert C Miller; Aminah Jatoi; Jeff A Sloan
Journal:  Support Care Cancer       Date:  2011-09-16       Impact factor: 3.603

3.  Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

Authors:  Shaad E Abdullah; Missak Haigentz; Bilal Piperdi
Journal:  Chemother Res Pract       Date:  2012-09-11

4.  A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.

Authors:  Janja Ocvirk; Steffen Heeger; Philip McCloud; Ralf-Dieter Hofheinz
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.